229 related articles for article (PubMed ID: 23102599)
1. Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients.
Maiolino G; Pedon L; Cesari M; Frigo AC; Barisa M; Rossitto G; Seccia TM; Zanchetta M; Rossi GP
Int J Cardiol; 2013 Sep; 168(1):484-9. PubMed ID: 23102599
[TBL] [Abstract][Full Text] [Related]
2. Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction.
Crisby M; Henareh L; Agewall S
Angiology; 2014 Nov; 65(10):932-6. PubMed ID: 24288363
[TBL] [Abstract][Full Text] [Related]
3. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.
Asciutto G; Dias NV; Edsfeldt A; Alm R; Fredrikson GN; Gonçalves I; Nilsson J
Atherosclerosis; 2015 Apr; 239(2):289-94. PubMed ID: 25682025
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients.
Rossi GP; Cesari M; De Toni R; Zanchetta M; Maiolino G; Pedon L; Ganzaroli C; Maiolino P; Pessina AC
Circulation; 2003 Nov; 108(20):2467-72. PubMed ID: 14581399
[TBL] [Abstract][Full Text] [Related]
5. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?
Finckh A; Courvoisier DS; Pagano S; Bas S; Chevallier-Ruggeri P; Hochstrasser D; Roux-Lombard P; Gabay C; Vuilleumier N
Arthritis Care Res (Hoboken); 2012 Jun; 64(6):817-25. PubMed ID: 22302385
[TBL] [Abstract][Full Text] [Related]
8. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris.
Doo YC; Han SJ; Lee JH; Cho GY; Hong KS; Han KR; Lee NH; Oh DJ; Ryu KH; Rhim CY; Lee KH; Lee Y
Am J Cardiol; 2004 Mar; 93(5):554-8. PubMed ID: 14996578
[TBL] [Abstract][Full Text] [Related]
9. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
[TBL] [Abstract][Full Text] [Related]
10. Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.
Nowak B; Madej M; Łuczak A; Małecki R; Wiland P
Adv Clin Exp Med; 2016; 25(1):43-50. PubMed ID: 26935497
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH
Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
13. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals.
Cotoi OS; Dunér P; Ko N; Hedblad B; Nilsson J; Björkbacka H; Schiopu A
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):202-10. PubMed ID: 24202303
[TBL] [Abstract][Full Text] [Related]
14. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Amioka N; Miyoshi T; Otsuka H; Yamada D; Takaishi A; Ueeda M; Hirohata S; Ito H
J Cardiol; 2019 Sep; 74(3):258-266. PubMed ID: 30898480
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein particle number predicts coronary artery calcification in asymptomatic adults at intermediate risk of cardiovascular disease.
Prado KB; Shugg S; Backstrand JR
J Clin Lipidol; 2011; 5(5):408-13. PubMed ID: 21981843
[TBL] [Abstract][Full Text] [Related]
16. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients.
Rossi GP; Maiolino G; Zanchetta M; Sticchi D; Pedon L; Cesari M; Montemurro D; De Toni R; Zavattiero S; Pessina AC
J Am Coll Cardiol; 2006 Sep; 48(6):1166-74. PubMed ID: 16979000
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody against, malondialdehyde-modified low density lipoprotein in patients with non-diabetic unstable angina: a potential role in immunologic reaction of plaque instability.
Kwon KH; Kwon HM; Hong BK; Kim DS; Lee JY; Ryu SK; Park BE; Park HY; Kim JH; Yoon YW; Cho SY; Kim HS
Yonsei Med J; 2002 Apr; 43(2):203-10. PubMed ID: 11971214
[TBL] [Abstract][Full Text] [Related]
18. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
Tsimikas S; Bergmark C; Beyer RW; Patel R; Pattison J; Miller E; Juliano J; Witztum JL
J Am Coll Cardiol; 2003 Feb; 41(3):360-70. PubMed ID: 12575961
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.
Maiolino G; Pedon L; Cesari M; Frigo AC; Wolfert RL; Barisa M; Pagliani L; Rossitto G; Seccia TM; Zanchetta M; Rossi GP
PLoS One; 2012; 7(10):e48171. PubMed ID: 23118945
[TBL] [Abstract][Full Text] [Related]
20. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
